17 July 2018 
EMA/492325/2018  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Nucala/ mepolizumab 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package 
See Annex A 
size(s): 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  GlaxoSmithKline Trading Services Limited 
Currabinny 
Carrigaline 
County Cork 
IRELAND 
Procedure  
Procedure number: 
EMEA/H/C/003860/II/0013/G 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0239/2017. For the purpose of the application of Article 45(3) of Regulation (EC) No 
1901/2006, significant studies in the agreed paediatric investigation plan P/0239/2017 were completed 
after the entry into force of that Regulation, 
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance 
with the agreed completed paediatric investigation plan P/0239/2017 is included in the technical 
dossier.  
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
 
  
 
 
 
 
 
 
 
 
  
